CCORF analyst Whitney Ijem maintains $Vertex Pharmaceuticals (VRTX.US)$ with a sell rating, and adjusts the target price from $361 to $408.
According to TipRanks data, the analyst has a success rate of 45.7% and a total average return of 5.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Vertex Pharmaceuticals (VRTX.US)$'s main analysts recently are as follows:
Following Vertex Pharmaceuticals' third-quarter results surpassing consensus estimates and the upward adjustment of its 2024 revenue forecast by approximately 1% at the midpoint, anticipation is building for the forthcoming suzetrigine Phase 2 lumbosacral radiculopathy data, which is projected to be released by the end of the year.
The company's robust performance in cystic fibrosis, which surpassed expectations, underscores the ongoing strength of its central business line, potentially supporting the stock's elevated valuation. However, caution is advised as the approach to FY25 might present more complexities compared to FY24. The forthcoming LSR data on suzetregine is anticipated to meet efficacy expectations, though it may not generate significant enthusiasm. Additionally, launches in the acute pain segment and for Casgevy are expected to progress at a gradual pace.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
CCORF分析师Whitney Ijem维持$福泰制药 (VRTX.US)$卖出评级，并将目标价从361美元上调至408美元。
根据TipRanks数据显示，该分析师近一年总胜率为45.7%，总平均回报率为5.0%。
此外，综合报道，$福泰制药 (VRTX.US)$近期主要分析师观点如下：
福泰制药第三季度业绩超过共识预期，2024年营业收入预测中值调整约1%，市场对即将公布的suzetrigine二期腰骶神经根痛数据的预期正在增加，预计将于年底发布。
公司在囊性纤维化领域的强劲表现超出预期，彰显了其核心业务线持续实力，可能支持股票高估值。然而，需要谨慎，因为FY25的方法可能比FY24更复杂。预计即将公布的suzetregine LSR数据将符合疗效预期，尽管可能不会引发显著热情。此外，急性疼痛领域和Casgevy的推出预计将以逐步的速度进行。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
